RE: Ouch, just seen that9 Mar 2024 23:31
I just cant get my head round why the prescriptions growth has dropped off so badly in Q4. This was supposed to be when the 100 strong sales team got bedded in properly and would be running at full speed. Yet they managed a 4.8k increase in Q2 over Q1 (when the full team had not even been hired & trained), yet only 5.3k in Q4 over Q3. Or to put it another way, each sales rep (on average) contributed to an additional TX of 17 per month. Which just seems shocking, no other word for it. Comparing Q3 & Q4 2022, there was a 26 tx increase per sales rep (as I understand they had only 25 reps at that point), without the new marketing campaign and strengthen sales management team and each rep covering a smaller area (thus having a more targeted approach). I bet some reps are doing much better than 17 per month, which means some are probably contributing to single figure TX growth. Something has/is going wrong on the sales front. Lost a lot on this one and still holding 3/4 of my original investment. My fault (although CEO has a lot to answer for!), but I just didn't see sales growth slipping this badly.